
Drug makers, insurers and pharmacy benefit managers face mounting pressure from Congress and the public to reduce the high list prices of drugs like insulin.
By KATIE THOMAS from NYT Health https://ift.tt/2FSv7Zc
via IFTTT
Diabetes, Insulin, Health Insurance and Managed Care, Drugs (Pharmaceuticals), your-feed-science
Source The New York Times
Làm đẹp Blog 247
Không có nhận xét nào:
Đăng nhận xét